BG Medicine halves IPO price
BG Medicine Inc. has re-priced its initial public offering at about half what it was shooting for in December, lowering its total IPO fundraise to $33.3 million, according to an amended regulatory document filed this morning.
BG withdrew its IPO from the cusp of public trading in December. At the time, it had planned to price at $13 to $15 a share. The Waltham developer of cardiac diagnostics is offering 4.75 million shares.